Go to main content
Back to Back to Immunovia.com
SV EN

News Published

Annual Report 2025

2025 – The year Immunovia launched PancreaSure and transitioned to a commercial company.

Skärmavbild 2026-08-24 kl. 12.38.53

In 2025, Immunovia achieved a major milestone by launching PancreaSure, a next-generation blood test for early detection of pancreatic cancer, in the United States. The company transitioned from a development-stage organization to a commercial enterprise, building momentum across clinical, regulatory, and commercial fronts.

READ THE FULL REPORT HERE.

Reports and presentations

Here you will find annual reports, interim reports, year-end reports and presentations from capital markets days.

To all reports

More news

shutterstock_2362754341

Investment case

Read about Immunovia as an investment here.

Published: 5 November, 2026

Jeff_Adam

Watch Immunovia's Q3 presentation

On November 2nd 2026, CEO Jeff Borcherding and CFO Adam Bäckström presented the report. Watch the webcast...

Published: 2 November, 2026

Immunovia Q3 bild

Immunovia's Q3 report

Read Immunovia's interim report for the third quarter.

Published: 2 November, 2026

Cookies

This website uses cookiesfor statistics and user experience.

This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.

Feel free to read our privacy policy. If you agree to our use, choose Allow all. If you want to change your choice afterwards, you will find that option at the bottom of the page.